The rs11385942 and rs657152 variants are not associated with COVID-19 severity and outcomes in patients treated with favipiravir and remdesivir

Background. There is a mounting evidence in the scientific literature that susceptibility to SARS-CoV-2 infection could vary. The severity of COVID-19 symptoms can  range from asymptomatic to severe respiratory failure, requiring prolonged artificial ventilation. The underlying causes of this range of clinical manifestations remain unclear. Identification of the risk factors that may cause this variation in clinical symptoms is important for identifying the most susceptible populations at highest risk. This should help improve prevention measures, reduce hospitalizations, and decrease the mortality rate of the disease. Previously, an association has been found between the severity of COVID-19 and the genetic markers rs11385942 G>GA and rs657152 A>C.

The aim. To assess the impact of carrying polymorphic markers rs11385942 G>GA and rs657152 A>C on the severity of COVID-19 in patients undergoing specific therapy. Materials and methods. A total of 240 patients hospitalized with a coronavirus infection were included in the study. All patients received therapy with favipiravir or remdesivir. The presence of the rs11385942 G>GA and rs657152 A>C variants was determined in all patients. The study compared the length of hospital stays, frequency of patient transfers to the intensive care unit (ICU), and frequency of clinical outcomes (recovery or death) among carriers of allelic variants of the markers under investigation.

Results. There were no significant associations between the carriage of variants rs11385942 G>GA and rs657152 A>C and the duration of patients’ hospitalization, frequency of patient transfers to the ICU, and patient outcomes.

Conclusion. The carriage of rs11385942 G>GA and rs657152 A>C variants did not affect the severity or type of clinical outcomes in patients with COVID-19.

1. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3): 269-271. doi: 10.1038/s41422-020-0282-0

2. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020; 14(1): 58-60. doi: 10.5582/ddt.2020.01012

3. The provisional guidelines. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19); 18th ed. Moscow: Ministry of Health of the Russian Federation; 2023. (In Russ.).

4. Stawicki SP, Jeanmonod R, Miller AC, Paladino L, Gaieski DF, Yaffee AQ, et al. The 2019–2020 novel coronavirus (severe acute respiratory syndrome coronavirus 2) pandemic: A joint American College of Academic International Medicine-World Academic Council of Emergency Medicine multidisciplinary COVID-19 working group consensus paper. J Glob Infect Dis. 2020; 12(2): 47-93. doi: 10.4103/jgid.jgid_86_20

5. Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P, et al. Genomewide association study of severe Covid-19 with respiratory failure. N Engl J Med. 2020; 383(16): 1522-1534. doi: 10.1056/NEJMoa2020283

6. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13): 1239-1242. doi: 10.1001/jama.2020.2648

7. He F, Deng Y, Li W. Coronavirus disease 2019: What we know? J Med Virol. 2020; 92(7): 719-725. doi: 10.1002/jmv.25766

8. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382(18): 1708-1720. doi: 10.1056/NEJMoa2002032

9. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8(5): 475-481. doi: 10.1016/S2213-2600(20)30079-5

10. Li X, Ma X. Acute respiratory failure in COVID-19: Is it “typical” ARDS? Crit Care. 2020; 24(1): 198. doi: 10.1186/s13054-020-02911-9

11. Fink-Baldauf IM, Stuart WD, Brewington JJ, Guo M, Maeda Y. CRISPRi links COVID-19 GWAS loci to LZTFL1 and RAVER1. EBioMedicine. 2022; 75: 103806. doi: 10.1016/j.ebiom.2021.103806

12. Balanovsky O, Petrushenko V, Mirzaev K, Abdullaev S, Gorin I, Chernevskiy D, et al. Variation of genomic sites associated with severe Covid-19 across populations: Global and national patterns. Pharmgenomics Pers Med. 2021; 14: 1391-1402. doi: 10.2147/PGPM.S320609

13. Orlova EA, Ogarkov OB, Khromova PA, Sinkov VV, Khasnatinov MA, Zhdanova SN, et al. SNP rs657152 is not associated with the level of viral load in COVID-19 or the probability of disease in the population of Caucasians in Eastern Siberia. Russian Journal of Genetics. 2021; 57(8): 982-984. (In Russ.). doi: 10.31857/S0016675821080099

14. Marçalo R, Neto S, Pinheiro M, Rodrigues AJ, Sousa N, Santos MAS, et al. Evaluation of the genetic risk for COVID-19 outcomes in COPD and differences among worldwide populations. PLoS One. 2022; 17(2): e0264009. doi: 10.1371/journal.pone.0264009